S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
MarketBeat Week in Review – 6/4 - 6/9
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
How major US stock indexes fared Friday 6/9/2023
FuelCell Is Back To Realistic Valuation
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
New Mexico reaches $500M settlement with Walgreens in opioid case
With GM and Ford embracing Tesla's EV charging technology, here's what it means for consumers
[Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
Nigeria's central bank chief arrested after being suspended by president
Closing prices for crude oil, gold and other commodities
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
MarketBeat Week in Review – 6/4 - 6/9
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
How major US stock indexes fared Friday 6/9/2023
FuelCell Is Back To Realistic Valuation
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
New Mexico reaches $500M settlement with Walgreens in opioid case
With GM and Ford embracing Tesla's EV charging technology, here's what it means for consumers
[Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
Nigeria's central bank chief arrested after being suspended by president
Closing prices for crude oil, gold and other commodities
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
MarketBeat Week in Review – 6/4 - 6/9
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
How major US stock indexes fared Friday 6/9/2023
FuelCell Is Back To Realistic Valuation
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
New Mexico reaches $500M settlement with Walgreens in opioid case
With GM and Ford embracing Tesla's EV charging technology, here's what it means for consumers
[Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
Nigeria's central bank chief arrested after being suspended by president
Closing prices for crude oil, gold and other commodities
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
MarketBeat Week in Review – 6/4 - 6/9
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
How major US stock indexes fared Friday 6/9/2023
FuelCell Is Back To Realistic Valuation
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
New Mexico reaches $500M settlement with Walgreens in opioid case
With GM and Ford embracing Tesla's EV charging technology, here's what it means for consumers
[Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
Nigeria's central bank chief arrested after being suspended by president
Closing prices for crude oil, gold and other commodities
NASDAQ:CRNX

Crinetics Pharmaceuticals (CRNX) Stock Forecast, Price & News

$21.67
-0.29 (-1.32%)
(As of 06/9/2023 ET)
Compare
Today's Range
$21.60
$22.45
50-Day Range
$15.73
$23.60
52-Week Range
$15.23
$24.58
Volume
534,752 shs
Average Volume
470,374 shs
Market Capitalization
$1.17 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$45.50

Crinetics Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
110.0% Upside
$45.50 Price Target
Short Interest
Healthy
6.37% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.62
Upright™ Environmental Score
News Sentiment
1.08mentions of Crinetics Pharmaceuticals in the last 14 days
Based on 9 Articles This Week
Insider Trading
Selling Shares
$132,624 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($3.41) to ($3.46) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.33 out of 5 stars

Medical Sector

215th out of 988 stocks

Pharmaceutical Preparations Industry

95th out of 482 stocks


CRNX stock logo

About Crinetics Pharmaceuticals (NASDAQ:CRNX) Stock

Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. The firm is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.

Receive CRNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Crinetics Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CRNX Stock News Headlines

Crinetics to Highlight Broad Pipeline at ENDO 2023
Unlock Profit Potential: Find Hidden Trade Opportunities Using A.I.
There’s a tool that scans and picks the best stocks…how you approach the trades is up to you. But when you’re forecasting 1 – 3 days in advance, it’s not really a guessing game. Stop guessing and start predicting to add consistency to your trades… no matter what happens in the market.
Where Crinetics Pharmaceuticals Stands With Analysts
Crinetics Pharmaceuticals (CRNX) Receives a Buy from Piper Sandler
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
Crinetics Pharmaceuticals (CRNX) Gets a Buy from Piper Sandler
The Latest Analyst Ratings for Crinetics Pharmaceuticals
See More Headlines

CRNX Price History

CRNX Company Calendar

Last Earnings
11/05/2021
Today
6/10/2023
Next Earnings (Estimated)
8/11/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CRNX
Fax
N/A
Employees
143
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$45.50
High Stock Price Forecast
$56.00
Low Stock Price Forecast
$35.00
Forecasted Upside/Downside
+110.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-163,920,000.00
Net Margins
-4,090.69%
Pretax Margin
-4,090.69%

Debt

Sales & Book Value

Annual Sales
$4.74 million
Book Value
$5.88 per share

Miscellaneous

Free Float
50,838,000
Market Cap
$1.17 billion
Optionable
Not Optionable
Beta
0.94

Key Executives

  • Scott R. Struthers
    President, Chief Executive Officer & Director
  • Jeff E Knight
    Chief Operating Officer
  • Marc J. S. Wilson
    Chief Financial Officer
  • Stephen F. BetzStephen F. Betz
    Chief Scientific Officer
  • Alan Seth Krasner
    Chief Medical Officer













CRNX Stock - Frequently Asked Questions

Should I buy or sell Crinetics Pharmaceuticals stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Crinetics Pharmaceuticals in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CRNX shares.
View CRNX analyst ratings
or view top-rated stocks.

What is Crinetics Pharmaceuticals' stock price forecast for 2023?

5 brokerages have issued 12 month price targets for Crinetics Pharmaceuticals' stock. Their CRNX share price forecasts range from $35.00 to $56.00. On average, they expect the company's stock price to reach $45.50 in the next year. This suggests a possible upside of 110.0% from the stock's current price.
View analysts price targets for CRNX
or view top-rated stocks among Wall Street analysts.

How have CRNX shares performed in 2023?

Crinetics Pharmaceuticals' stock was trading at $18.30 at the beginning of the year. Since then, CRNX stock has increased by 18.4% and is now trading at $21.67.
View the best growth stocks for 2023 here
.

When is Crinetics Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, August 11th 2023.
View our CRNX earnings forecast
.

How were Crinetics Pharmaceuticals' earnings last quarter?

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) announced its earnings results on Friday, November, 5th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.72) by $0.01. Crinetics Pharmaceuticals had a negative trailing twelve-month return on equity of 52.55% and a negative net margin of 4,090.69%.

What is R. Scott Struthers, Ph.D.'s approval rating as Crinetics Pharmaceuticals' CEO?

6 employees have rated Crinetics Pharmaceuticals Chief Executive Officer R. Scott Struthers, Ph.D. on Glassdoor.com. R. Scott Struthers, Ph.D. has an approval rating of 100% among the company's employees. This puts R. Scott Struthers, Ph.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 68.0% of employees surveyed would recommend working at Crinetics Pharmaceuticals to a friend.

What other stocks do shareholders of Crinetics Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Crinetics Pharmaceuticals investors own include SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Aldeyra Therapeutics (ALDX), G1 Therapeutics (GTHX), Kura Oncology (KURA), Otonomy (OTIC), Selecta Biosciences (SELB), TG Therapeutics (TGTX), Arbutus Biopharma (ABUS) and Applied Genetic Technologies (AGTC).

When did Crinetics Pharmaceuticals IPO?

(CRNX) raised $80 million in an initial public offering on Wednesday, July 18th 2018. The company issued 5,000,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Leerink Partners and Piper Jaffray served as the underwriters for the IPO.

What is Crinetics Pharmaceuticals' stock symbol?

Crinetics Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRNX."

Who are Crinetics Pharmaceuticals' major shareholders?

Crinetics Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.33%), Wellington Management Group LLP (6.73%), Perceptive Advisors LLC (6.58%), State Street Corp (4.11%), Braidwell LP (3.74%) and First Light Asset Management LLC (3.00%). Insiders that own company stock include Ajay Madan, Coelho Rogerio Vivaldi, Dana Pizzuti, Jeff E Knight, Matthew K Fust, Perceptive Advisors Llc, Richard Scott Struthers and Stephen F Betz.
View institutional ownership trends
.

How do I buy shares of Crinetics Pharmaceuticals?

Shares of CRNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Crinetics Pharmaceuticals' stock price today?

One share of CRNX stock can currently be purchased for approximately $21.67.

How much money does Crinetics Pharmaceuticals make?

Crinetics Pharmaceuticals (NASDAQ:CRNX) has a market capitalization of $1.17 billion and generates $4.74 million in revenue each year. The company earns $-163,920,000.00 in net income (profit) each year or ($3.28) on an earnings per share basis.

How many employees does Crinetics Pharmaceuticals have?

The company employs 143 workers across the globe.

How can I contact Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals' mailing address is 10222 Barnes Canyon Road Building #2, San Diego CA, 92121. The official website for the company is www.crinetics.com. The company can be reached via phone at (858) 450-6464 or via email at ir@crinetics.com.

This page (NASDAQ:CRNX) was last updated on 6/10/2023 by MarketBeat.com Staff

My Account -